Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Blenoxane. Every FDA application for this active ingredient: 1 branded and 8 generic.
As of Nov 14, 2026, FDA lists 9 applications for Bleomycin Sulfate (sold as Blenoxane), first approved Jul 31, 1973, with 1 new use approved and 0 published complete response letters.
First approved: Jul 31, 1973
Applications: 9
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $41K
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Bleomycin Sulfate
Part B
$41K
-21%
890
Bleomycin Sulfate
Part D
$1K
-57%
0
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
BLEOMYCIN SULFATE 15 UNIT VIAL: $26.45 per unitGeneric · -17% in a year
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Bristol Myers Squibb
Hikma
Fresenius Kabi USA
Cipla